Covid-19 treatment: Sun Pharma gets DCGI approval for Nafamostat clinical trial in patients
Team Udayavani, May 30, 2020, 4:04 PM IST
The Drug Controller General of India has approved Sun Pharmaceutical Industries Ltd’s clinical trial with nafamostat mesilate in covid-19 patients
Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of disseminated intravascular coagulation (DIC)
Scientists from the University of Tokyo in Japan and Leibniz Institute for Primate Research in Germany recently demonstrated that Nafamostat at very low concentrations suppresses a protein that the Covid-19 virus uses to enter human lung cells.
Dilip Shanghvi, Managing Director, Sun Pharma said, “Sun Pharma is constantly evaluating potential targets that can be explored for treating Covid-19 patients. Nafamostat has shown promising data against SARS-CoV-2 virus in in-vitro studies conducted by three independent groups of scientists in Europe, Japan and South Korea. We believe it holds promise in the treatment of Covid-19 patients
Sun Pharma is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Traffic noise can increase risk of cardiovascular disease: Study
Nearsightedness is at epidemic levels – and the problem begins in childhood
Study finds genetic basis for link between depression, heart disease
World Malaria Day: WHO calls for equitable health access
What role does genetics play in breast cancer? How can genetic testing help with early breast cancer diagnosis?
MUST WATCH
Latest Additions
Bengaluru maximum temperature hit 38.5 degree Celsius on Sunday: IMD
Private players will make space more accessible: ISRO chief
‘Doctored’ videos of Amit Shah: Delhi Police register case after MHA plaint
EC asks AAP to modify campaign song, party dismisses request
‘Defeat Shettar, the way he was defeated in Hubballi’